Disc Medicine stock drops 22% after FDA letter prompts investigation

Rosen Law Firm has opened an investigation into Disc Medicine, Inc. (NASDAQ: IRON) on behalf of shareholders, citing allegations that the company may have issued misleading business information to investors.

The investigation stems from a press release issued by the investor rights law firm, which is preparing a class action to recover investor losses.

The central issue is the U.S. Food and Drug Administration’s (FDA) Complete Response Letter (CRL) issued on February 13, 2026, regarding Disc Medicine's bitopertin program. The FDA stated it could not approve the new drug application in its current form, requesting additional evidence. On the day of the announcement, Disc Medicine's stock price fell 22%.

The investigation exposes Disc Medicine to significant legal and financial risk, potentially leading to a costly class-action lawsuit. For investors who purchased shares before the disclosure, the probe offers a potential avenue to recover losses sustained after the 22% stock price decline.

The Rosen Law Firm is encouraging investors who purchased Disc Medicine securities to inquire about joining a prospective class action. The firm, which specializes in securities class actions, has a track record of securing large settlements for investors.

This investigation into Disc Medicine highlights the potential risks for shareholders when a company faces regulatory setbacks. The outcome of the probe and any subsequent legal action will be a key catalyst for the stock's performance in the near future.

This article is for informational purposes only and does not constitute investment advice.